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Objective: Sham surgery (placebo surgery) is an intervention that omits the step thought to be thera-
peutically necessary. In surgical clinical trials, sham surgery serves an analogous purpose to placebo
drugs, neutralizing biases such as the placebo effect. A critical review was performed to study the sta-
tistical relevance of the clinical trials about sham surgery in the light of potential confounding factors.
Materials and methods: For the critical review 52 articles were included. The possible confounding
factors have been studied using a structured interpretative research form designed by the authors. This
form includes the following ten confounding factors: I), lack of homogeneity among inclusion/exclusion
criteria. II), false double blind. III), lack of post-surgery double blind. IV), power of the study. V), sample
characteristics. VI), lost patients to Follow-up. VII), gender distribution. VIII), age equilibrium. IX), lack of
psychological patient evaluation. X), lack of psychiatric patient evaluation. In most of the studies, at least
one confounding factor was present.
Results: The analysis of the confounding factors showed that they could inﬂuence the reliability of the
surgical placebo effects.
Conclusions: The validity of sham surgery should be reconsidered.
© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Sham surgery (placebo surgery) is a surgical intervention that
omits the step thought to be therapeutically necessary. In clinical
trials of surgical interventions, sham surgery serves an analogous
purpose to placebo drugs, neutralizing biases such as the placebo
effect [1].
New surgical procedures have been developed in the last years
and sometimes the acceptance of new procedures is based on their
perceived value relative to previously accepted treatments. This
process can be biased because inﬂuenced by the enthusiasm, skill,
and prominence of the surgeon reporting the results and by their
selection of patients for treatment [2].
A double-blinded randomized placebo-controlled trial is
recognized as the gold standard of clinical research [3e19]. “Trial” is
from Anglo-French “trier”, meaning “to try”, referring to the action
or process of putting something to test or proof at the bedside of
the patient. Broadly, clinical trial refers to any testing done on
human beings for determining the value of a treatment or for
preventing disease. The clinical trial, in simplest form, involves the
application of the experimental variable (treatment to a person or
group of persons) and follow-up observation of the treatment to
measure its effect. That outcome measure may be death, occur-
rence or recurrence of some morbid condition, or a difference
indicative of change. Trials are said to be controlled if the effect of
the treatment is measured against a comparison treatment
administered over the same time period and under similar
conditions.
The comparison treatment may be another test treatment or a
control treatment consisting of an accepted standard form of
therapy, a placebo or sham treatment, or observation only (no
treatment). Clinical trials evaluates the efﬁcacy of an intervention
towards a comparator of known efﬁcacy or towards a placebo. The
ideal of a clinical trial is that the researcher compares groups of
patients who differ only with respect their treatment. If the groups
differ by other characteristics then the comparison of treatments
can be biased. If these can be identiﬁed, their effects on the cause-
effect relation can be avoided, but unknown or unexpected biases
cannot be dealt with. The method to design a clinical trial must be
to avoid or to eliminate biases.
Some authors reported that placebo effect can be largely inﬂu-
enced by inadequate research methods producing artefacts [20].
Recently, a case-based ethical analysis on placebo in surgical
research based on the recommendations about clinical research
deﬁned in the Helsinki Declaration was performed. Authors
concluded focusing attention only on patient that should always
come before any other implication [21].
Confounding is referred to as a ”mix of effects” [22]. This de-
termines that the causal association mingles the effects of one or
more factors that can change the intensity or even reverse thisassociation in an unpredictable way the real association between
exposure and outcome, in presence of confounding factors, can be
mistakenly shown or failed to. In a clinical trial a known prognostic
factor, that is not evenly distributed between the groups in the
study, might underlie the presence of a confounding factor [23]. In a
randomized controlled trial the treatment arms are compared to a
control group that is treated with placebo (or no intervention) in
most medical specialty studies and pharmacology studies. How-
ever, in surgical trials, onwhichwe focused our interest, the use of a
placebo, or a “sham” surgery, is controversial. In the European
Union legislation (u) there is no speciﬁc or even general reference
to sham surgery. No directives on this issue was never addressed to
the Member States nor with the usual form of the ordinary legis-
lative procedure (European Council and European Parliament
together), nor with the least common form of the special legislative
procedures (sole legislator the European Council). Also, there is no
reference, even as recommendations, about acts of non-binding
guidelines to member states and issued by the organs of the
Unionwithout a binding regulatory powers and/or when the use of
the latter is not necessary. Because of the lack in literature of studies
and analysis of those trials from the confounding point of view, we
did this critical review using speciﬁc criteria of selection for the
articles to analyze. In synthesis, the aim of this paper is to analyze
all the trials regarding sham surgery in the light of confounder
factors. This analysis will be useful to highlight the real statistical
power of the best evidence available.
2. Materials and methods
2.1. Study design
A critical reviewwas performed according to the Critical Review
writing guidelines elaborated at the University of Technology of
Sydney (http://www.uts.edu.au/current-students/support/helps/
self-help-resources/academic-writing/critical-thinking-skills)
adapted from the following sources: Royce, T 2009, The meaning of
critical review, ELSSA Centre, UTS; Royce, T 2009, Skills to cultivate
for research and critical review, ELSSA Centre, UTS. Royce, T 2009,
Reading and writing critically, ELSSA Centre, UTS.
2.2. Inclusion and exclusion criteria
A total of 87 articles about sham surgery were found in PubMed
database up to May 31, 2015. Studies were eligible if they were
randomized clinical trials in which the efﬁcacy of surgery was
compared with placebo. Surgery is deﬁned as any interventional
procedure that changes the anatomy and requires a skin incision or
the use of endoscopic techniques; dental studies were excluded.
The term placebo refers to placebo surgery, or sham surgery, an
imitation procedure intended to mimic the active intervention;
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cedure was performed but patients underwent sedation or general
anesthesia and could not distinguish whether or not they had un-
dergone the actual procedure. Exclusion criteria were: studies
investigating anesthesia or other drugs; studies about major sur-
gery procedures were excluded because the post-operative evi-
dence of the treatment group is veriﬁable by the patient and health
care staff (third operator) that follow the patient after surgery.
Fifty-three clinical trials resulted eligible. One study of 53 was
excluded by the analysis because lack of informed consent and
inside the medical record the type of intervention was not truly.
Finally, 52 randomized clinical trial were eligible for the critical
review [10,24e73].2.3. Confounding factors
The possible confounding factors have been studied using a
structured interpretative research form designed by the authors
including the following ten confounding factors: I), lack of homo-
geneity among inclusion/exclusion criteria. II), false double blind.
III), lack of post-surgery double blind. IV), power of the study. V),
sample characteristics. VI), lost patients to follow-up. VII), gender
distribution. VIII), age equilibrium. IX), lack of psychological patient
evaluation. X), lack of psychiatric patient evaluation. The reasons
for choosing these items were: Methodological (items 1e3); Sta-
tistical (item 4e8) and Clinical (item 9e10). To evaluate the pres-
ence of these confounding factors, the interpretive research form
was applied to analyze the trials in order to record the ten items
above reported and the type of pathology, the type of surgery
(simulated or performed).
No evaluation regarding administrative treatment was per-
formed because this information lack in the trials. Therefore, the
economic inﬂuence and the difference between naive patients and
not naïve patients on the confounding factors were not evaluated.Table 1
Characteristics of trial series.
Tabella n of Studies
Inclusion and exclusion criteria homogeneity 51/52 (98%)
Randomized 51/52 (98%)
Single blind 16/52 (31%)
Double blind 36/52 (69%)
Post-operative double blind 22/36 (61%)
Study power absence or <80% 32/52 (61%)
Sample size group presence 52/52 (100%)
Gender homogeneity 27/52 (51%)
Age homogeneity 45/52 (86%)
Psychological evaluation presence 16/52 (31%)
Psychiatric evaluation presence 10/52 (20%)
Table 2
Main results from the critical review of the 52 eligible studies.
Critical review results N (%)
Not homogeneity in gender 27/52 (52)
Patients age not reported 7/52 (13)
Inclusion and exclusion criteria homogeneity 1/52 (2)
Single-blind trials 16/52 (31)
Post-intervention trials 22/52 (42)
Double-blind trials 14/52 (27)
Power of the study not-mentioned 31/52 (60)
Power of the study under the threshold 1/52 (2)
Mean age value used for patients description 47/52 (90.4)
Median age value used for patients description 5/52 (9.6)
Absence of psychological proﬁle 36/52 (69)
Absence of psychiatric proﬁle 43/52 (82)Two independent reviewers performed data extraction and
analysis.
2.4. Statistical analysis
Data have been analyzed using MedCalc 13.2.2.0 (MedCalc
Software, Mariakerke, Belgium). The normal distribution of each
variable was tested by Kolmogorov-Smirnov test. Variables were
compared using Mann-Whitney's test for independent samples. A
p-value <0.05 was considered statistically signiﬁcant.
3. Results
The characteristics of the 52 randomized clinical trials analyzed
in the critical review are summarized in Table 1. The main results
from the critical review of the 52 eligible studies are reported in
Table 2. In 27 studies on 52 (52%) studies, a sort of “false random-
ization” has been used, resulting in not homogeneity in gender. In 7
on 52 studies (13%) authors did not report the age of the patient
enrolled. One on 52 studies (2%) reported homogeneity between
inclusion and exclusion criteria. Sixteen on 52 studies (31%) were
single blind trials, 22 on 52 (42%) were post intervention studies
and 14/52 (39%) classiﬁed as double blind trial. In 31 on 52 studies
(60%) the power of the study was not mentioned, while in the
remaining 21 only in one study the power was under the usual
threshold of 80% (Table 2).
The box plot analysis reported in Fig. 1, showed no difference
between the median sample size comparing sham and not-sham
surgery studies. The outliers, reported in Fig. 1, fall more
frequently in the not-sham group and could represent a potential
bias if a reliable meta-analysis of “confounding” has to be realized.
Regarding the median and mean values of the patient age, a
great homogeneity has been observed between “sham” and “not
sham” groups. As evidenced in Fig. 2, the age mean value has been
used for population description in themajority of the studies; in 47/
52 (90.4%) eligible studies the mean age value was used in both
arms, sham and not-sham surgery groups, whereas the median age
was used only in 5/52 (9.6%) studies (Table 2). In 35 on 47 studies
(77%) on mean age (Fig. 2), no difference between sham and not
sham arms was evident. Last, the absence of psychological and
psychiatric proﬁle has been noted in 36 on 52 (69%) and in 43 on 52
(82%) of the studies, respectively (Table 2).
Overall, 270 on 4697 (5%) participants were lost to the follow-
up.
4. Conclusion
Sham surgery (placebo surgery) is a surgical intervention
omitting the intended therapeutic procedure. The enrollment ofReferences
[10,24,25,27,30,32,36,38,39,41,42,47,49,54,55,57e63,65,66,69,72,74].
[40,44,58,59,69,72,73].
[65]
[26,27,31,40e42,44,45,51,55e57,62,66,67,69].
[25,26,28,32e35,39,43,48,49,52,58,60,63e65,70e74].
[10,29,30,36e38,46,47,50,53,54,59,61,68].
[10,26,28,30,31,33e35,38,44,45,47e50,52,54,57e59,63e66,68e74].
[53]
[10,24e32,34e39,41,43,45,46,48e56,60e68,70,74].
[33,42,47,57,71]
[10,24,25,27,29e32,36e47,50,53e57,59e62,65e69,74].
[25e27,29e37,40e48,50e60,62e69,71e73].
Fig. 1. The distribution of sample sizes of trial series by study groups. The variable analysis was performed by Mann-Whitney's test for independent samples.
Fig. 2. Studies reporting mean age in each arm; Studies reporting median age in each arm.
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sham surgical procedure has necessarily produced a lively debate
about the ethical acceptability [8,18,19,74,75].
The role of the surgical placebo is fervently debated [76].
Some Authors raised doubts about the reliability of the placebo
effects suggesting the possibility that artefacts from inadequate
research methods could alter the results of the study [77].
Recently, Sihvonen et al. attempted to address these criticisms
discussing some methodological issues essential for successful
controlled surgical trial, minimizing bias and maximizing the val-
idity of the study [20].
Confounding factors can change the intensity or even reverse
the causal association between exposure and outcome [23]. The
lack in literature of studies and analysis on sham surgical trials from
the confounding point of view, this critical review should highlight
the real statistical power of the best evidence available on this
debated issue. The results of the critical review could suggest the
following conclusions: 1) these studies involving sham surgery,
which were published in medical literature, are exposed to a
number of confounders, which should be considered in further
analysis. 2) Given the number of confounding factors revealed by
this short analysis (i.e. true double blind, study power, sex and age
randomization, etc.) the validity of the use of sham surgery must be
reconsidered. 3) Sex and age are considered the most frequently
causes of confounding in the strength of the association measure in
cause-effect model. The lack of these two important classic con-
founding factors is indicative of the low scientiﬁc reliability of data
presented by these trials. 4) Because the different pathologies in
trials did not reach a number sufﬁcient for stratiﬁcation, data in the
whole was the unique type of analysis that could be performed. 5)
The presence of inter-study variability between sham and not sham
studies was not ascribable to mean or median age of patients but
possibly to other factors. 6) The absence of psychological and
psychiatric proﬁle that is relevant for studies were the placebo ef-
fect have to be evaluated represents a very important confounding
factor [10,22,24e73,78,79]. 7) A percentage of 5% of participants
lost to the follow-up has been extracted from 30 on the 52 studies
examined (ref.). This represents a limit and a further confounding
factors inﬂuencing sham or not sham surgery effectiveness.
In conclusion, confounding factors could inﬂuence the reliability
of the surgical placebo effects and have to be considered as po-
tential bias in controlled surgical trial. Given this inﬂuence, the
validity of sham surgery should be reconsidered.Ethical approval
Ethical Approval and Informed Consent, due to the type of
investigation, have not been necessary.Funding
The research has been carried out with no funding by sponsors.Author contribution
All authors have contributed as a group to all aspects of
publications.Conﬂicts of interest
All authors decline any ﬁnancial and personal conﬂicts of
interest.Guarantor
Massimiliano A Vitali.
Acknowledgments
We thank Jonathan George Hart for redactional overview.
References
[1] W. Rogers, K. Hutchison, Z.C. Skea, et al., Strengthening the ethical assessment
of placebo-controlled surgical trials: three proposals, BMC Med. Ethics 15
(2014) 78.
[2] A.J. London, J.B. Kadane, Sham surgery and genuine standards of care: can the
two be reconciled? Am. J. Bioeth. 3 (4) (2003) 61e64.
[3] P. Angelos, Sham surgery in research: a surgeon's view, Am. J. Bioeth. 3 (4)
(2003) 65e66.
[4] H.K. Beecher, Surgery as placebo. A quantitative study of bias, Jama 176 (1961)
1102e1107.
[5] C.C. Clark, The physician's role, “sham surgery,” and trust: a conﬂict of duties?
Am. J. Bioeth. 3 (4) (2003) 57e58.
[6] P.A. Clark, Placebo surgery for Parkinson's disease: do the beneﬁts outweigh
the risks? J. Law Med. Ethics 30 (1) (2002) 58e68.
[7] L.A. Cobb, G.I. Thomas, D.H. Dillard, et al., An evaluation of internal-mammary-
artery ligation by a double-blind technic, N. Engl. J. Med. 260 (22) (1959)
1115e1118.
[8] W. Dekkers, G. Boer, Sham neurosurgery in patients with Parkinson's disease:
is it morally acceptable? J. Med. Ethics 27 (3) (2001) 151e156.
[9] E.J. Emanuel, F.G. Miller, The ethics of placebo-controlled trialsea middle
ground, N. Engl. J. Med. 345 (12) (2001) 915e919.
[10] C.R. Freed, P.E. Greene, R.E. Breeze, et al., Transplantation of embryonic
dopamine neurons for severe Parkinson's disease, N. Engl. J. Med. 344 (10)
(2001) 710e719.
[11] T.B. Freeman, D.E. Vawter, P.E. Leaverton, et al., Use of placebo surgery in
controlled trials of a cellular-based therapy for Parkinson's disease, N. Engl. J.
Med. 341 (13) (1999) 988e992.
[12] S. Horng, F.G. Miller, Is placebo surgery unethical? N. Engl. J. Med. 347 (2)
(2002) 137e139.
[13] A.G. Johnson, Surgery as a placebo, Lancet 344 (8930) (1994) 1140e1142.
[14] World medical association declaration of Helsinki. Recommendations guiding
physicians in biomedical research involving human subjects, Jama 277 (11)
(1997) 925e926.
[15] J. Katz, The nuremberg code and the nuremberg trial. A reappraisal, Jama 276
(20) (1996) 1662e1666.
[16] G. Knutsen, L. Engebretsen, T.C. Ludvigsen, et al., Autologous chondrocyte
implantation compared with microfracture in the knee. A randomized trial,
J. Bone Jt. Surg. Am. 86-a (3) (2004) 455e464.
[17] H.S. Leeds, Social aspects of sham surgeries, Am. J. Bioeth. 3 (4) (2003) 70e71.
[18] R. Macklin, The ethical problems with sham surgery in clinical research,
N. Engl. J. Med. 341 (13) (1999) 992e996.
[19] F.G. Miller, Sham surgery: an ethical analysis, Am. J. Bioeth. 3 (4) (2003)
41e48.
[20] R. Sihvonen, M. Paavola, A. Malmivaara, et al., Finnish degenerative meniscal
lesion study (FIDELITY): a protocol for a randomised, placebo surgery
controlled trial on the efﬁcacy of arthroscopic partial meniscectomy for pa-
tients with degenerative meniscus injury with a novel 'RCT within-a-cohort'
study design, BMJ Open 3 (3) (2013).
[21] S. Hostiuc, I. Rentea, E. Drima, et al., Placebo in surgical research: a case-based
ethical analysis and practical consequences, Biomed. Res. Int. 2016 (2016)
2627181.
[22] K.J. Rothman, S. Greenland, T.L. Lash, Modern Epidemiology, Wolters Kluwer
Health/Lippincott Williams & Wilkins, 2008.
[23] A.C. Skelly, J.R. Dettori, E.D. Brodt, Assessing bias: the importance of consid-
ering confounding, Evid. Based Spine Care J. 3 (1) (2012) 9e12.
[24] M.B. Gillespie, P.E. Wylie, T. Lee-Chiong, et al., Effect of palatal implants on
continuous positive airway pressure and compliance, Otolaryngol. Head. Neck
Surg. 144 (2) (2011) 230e236.
[25] D.L. Steward, T.C. Huntley, B.T. Woodson, et al., Palate implants for obstructive
sleep apnea: multi-institution, randomized, placebo-controlled study, Oto-
laryngol. Head. Neck Surg. 139 (4) (2008) 506e510.
[26] H.J. Davys, D.E. Turner, P.S. Helliwell, et al., Debridement of plantar callosities
in rheumatoid arthritis: a randomized controlled trial, Rheumatology 44 (2)
(2005) 207e210.
[27] J. Deviere, G. Costamagna, H. Neuhaus, et al., Nonresorbable copolymer im-
plantation for gastroesophageal reﬂux disease: a randomized sham-controlled
multicenter trial, Gastroenterology 128 (3) (2005) 532e540.
[28] A. Genco, M. Cipriano, V. Bacci, et al., BioEnterics (R) Intragastric Balloon (BIB
(R)): a short-term, double-blind, randomised, controlled, crossover study on
weight reduction in morbidly obese patients, Int. J. Obes. Lond. 30 (1) (2006)
129e133.
[29] J. Arts, R. Bisschops, K. Blondeau, et al., A double-blind sham-controlled study
of the effect of radiofrequency energy on symptoms and distensibility of the
M. Ciccozzi et al. / Annals of Medicine and Surgery 12 (2016) 21e2626gastro-esophageal junction in GERD, Am. J. Gastroenterol. 107 (2) (2012)
222e230.
[30] D. Fleischer, Endoscopic Nd:YAG laser therapy for active esophageal variceal
bleeding. A randomized controlled study, Gastrointest. Endosc. 31 (1) (1985)
4e9.
[31] G.M. Fullarton, G.G. Birnie, A. MacDonald, et al., Controlled trial of heater
probe treatment in bleeding peptic ulcers, Br. J. Surg. 76 (6) (1989) 541e544.
[32] M. Friedman, P. Schalch, H.-C. Lin, et al., Palatal implants for the treatment of
snoring and obstructive sleep apnea/hypopnea syndrome, Otolaryngol. Head.
Neck Surg. 138 (2) (2008) 209e216.
[33] M. Bajbouj, V. Becker, F. Eckel, et al., Argon plasma coagulation of cervical
heterotopic gastric mucosa as an alternative treatment for globus sensations,
Gastroenterology 137 (2) (2009) 440e444.
[34] C.H.M. van Schie, A. Whalley, L. Vileikyte, et al., Efﬁcacy of injected liquid
silicone in the diabetic foot to reduce risk factors for ulceration - a randomized
double-blind placebo-controlled trial, Diabetes Care 23 (5) (2000) 634e638.
[35] C.C. Thompson, B. Chand, Y.K. Chen, et al., Endoscopic Suturing for transoral
outlet reduction increases weight loss after Roux-en-Y gastric bypass Surgery,
Gastroenterology 145 (1) (2013) 129.
[36] G.D. Silverberg, M. Mayo, T. Saul, et al., Continuous CSF drainage in AD - re-
sults of a double-blind, randomized, placebo-controlled study, Neurology 71
(3) (2008) 202e209.
[37] A. Dowson, M.J. Mullen, R. Peatﬁeld, et al., Migraine intervention with
STARFlex technology (MIST) trial - a prospective, multicenter, double-blind,
sham-controlled trial to evaluate the effectiveness of patent foramen ovale
closure with STARFlex septal repair implant to resolve refractory migraine
headache, Circulation 117 (11) (2008) 1397e1404.
[38] C.W. Olanow, C.G. Goetz, J.H. Kordower, et al., A double-blind controlled trial
of bilateral fetal nigral transplantation in Parkinson's disease, Ann. Neurol. 54
(3) (2003) 403e414.
[39] B.J.C. Freeman, R.D. Fraser, C.M.J. Cain, et al., A randomized, double-blind,
controlled trial - intradiscal electrothermal therapy versus placebo for the
treatment of chronic discogenic low back pain, Spine 30 (21) (2005)
2369e2377.
[40] L.J. Back, T. Liukko, I. Rantanen, et al., Radiofrequency surgery of the soft palate
in the treatment of mild obstructive sleep apnea is not effective as a single-
stage procedure: a randomized single-blinded placebo-controlled trial,
Laryngoscope 119 (8) (2009) 1621e1627.
[41] P. Hartigan, Sclerotherapy for male alcoholic cirrhotic patients who have bled
from esophageal varices: results of a randomized, multicenter clinical trial,
Hepatology 20 (3) (1994) 618e625.
[42] G.W. Stone, P.S. Teirstein, R. Rubenstein, et al., A prospective, multicenter,
randomized trial of percutaneous transmyocardial laser revascularization in
patients with nonrecanalizable chronic total occlusions, J. Am. Coll. Cardiol. 39
(10) (2002) 1581e1587.
[43] M. Salem, S. Rotevatn, S. Stavnes, et al., Usefulness and safety of percutaneous
myocardial laser revascularization for refractory angina pectoris, Am. J. Car-
diol. 93 (9) (2004) 1086e1091.
[44] J.E. Geenen, W.J. Hogan, W.J. Dodds, et al., The efﬁcacy of endoscopic
sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi
dysfunction, N. Engl. J. Med. 320 (2) (1989) 82e87.
[45] R. Rothstein, C. Filipi, K. Caca, et al., Endoscopic full-thickness plication for the
treatment of gastroesophageal reﬂux disease: a randomized, sham-controlled
trial, Gastroenterology 131 (3) (2006) 704e712.
[46] N.J. Shaheen, P. Sharma, B.F. Overholt, et al., Radiofrequency ablation in Bar-
rett's esophagus with dysplasia, N. Engl. J. Med. 360 (22) (2009) 2277e2288.
[47] C.J.G. Sutton, S.P. Ewen, N. Whitelaw, et al., Prospective, randomized, double-
blind, controlled trial of laser laparoscopy in the treatment of pelvic pain
associated with minimal, mild, and moderate endometriosis, Fertil. Steril. 62
(4) (1994) 696e700.
[48] M. Castro, A.S. Rubin, M. Laviolette, et al., Effectiveness and safety of bronchial
thermoplasty in the treatment of severe asthma a multicenter, randomized,
double-blind, sham-controlled clinical trial, Am. J. Respir. Crit. Care Med. 181
(2) (2010) 116e124.
[49] J. Abbott, J. Hawe, D. Hunter, et al., Laparoscopic excision of endometriosis: a
randomized, placebo-controlled trial, Fertil. Steril. 82 (4) (2004) 878e884.
[50] B.A. Stuck, A. Sauter, K. Hormann, et al., Radiofrequency surgery of the soft
palate in the treatment of snoring. A placebo-controlled trial, Sleep 28 (7)
(2005) 847e850.
[51] D.J. Swank, S.C.G. Swank-Bordewijk, W.C.J. Hop, et al., Laparoscopic adhe-
siolysis in patients with chronic abdominal pain: a blinded randomised
controlled multi-centre trial, Lancet 361 (9365) (2003) 1247e1251.
[52] J.D. Bradley, D.K. Heilman, B.P. Katz, et al., Tidal irrigation as treatment for
knee osteoarthritis - a sham-controlled, randomized, double-blinded evalu-
ation, Arthritis Rheum. 46 (1) (2002) 100e108.
[53] B. Guyuron, D. Reed, J.S. Kriegler, et al., A placebo-controlled surgical trial of
the treatment of migraine headaches, Plast. Reconstr. Surg. 124 (2) (2009)
461e468.[54] M.P. Schwartz, H. Wellink, H.G. Gooszen, et al., Endoscopic gastroplication for
the treatment of gastro-oesophageal reﬂux disease: a randomised, sham-
controlled trial, Gut 56 (1) (2007) 20e28.
[55] K.J. Pauza, S. Howell, P. Dreyfuss, et al., A randomized, placebo-controlled trial
of intradiscal electrothermal therapy for the treatment of discogenic low back
pain, Spine J. 4 (1) (2004) 27e35.
[56] M. Montgomery, B. Hakanson, O. Ljungqvist, et al., Twelve months' follow-up
after treatment with the EndoCinch endoscopic technique for gastro-
oesophageal reﬂux disease: a randomized, placebo-controlled study, Scand.
J. Gastroenterol. 41 (12) (2006) 1382e1389.
[57] R.B. Hogan, J.H. Johnston, B.W. Long, et al., A double-blind, randomized, sham-
controlled trial of the gastric bubble for obesity, Gastrointest. Endosc. 35 (5)
(1989) 381e385.
[58] J. Jarrell, R. Mohindra, S. Ross, et al., Laparoscopy and reported pain among
patients with endometriosis, J. Obstet. Gynaecol. Can. 27 (5) (2005) 477e485.
[59] D.F. Kallmes, B.A. Comstock, P.J. Heagerty, et al., A randomized trial of verte-
broplasty for osteoporotic spinal fractures, N. Engl. J. Med. 361 (6) (2009)
569e579.
[60] R.E. Gross, R.L. Watts, R.A. Hauser, et al., Intrastriatal transplantation of
microcarrier-bound human retinal pigment epithelial cells versus sham sur-
gery in patients with advanced Parkinson's disease: a double-blind, rando-
mised, controlled trial, Lancet Neurol. 10 (6) (2011) 509e519.
[61] R. Buchbinder, R.H. Osborne, P.R. Ebeling, et al., A randomized trial of verte-
broplasty for painful osteoporotic vertebral fractures, N. Engl. J. Med. 361 (6)
(2009) 557e568.
[62] P.E. Lee, R.C. Kung, H.P. Drutz, Periurethral autologous fat injection as treat-
ment for female stress urinary incontinence: a randomized double-blind
controlled trial, J. Urol. 165 (1) (2001) 153e158.
[63] J.B. Moseley, K. O'Malley, N.J. Petersen, et al., A controlled trial of arthroscopic
surgery for osteoarthritis of the knee, N. Engl. J. Med. 347 (2) (2002) 81e88.
[64] D. Freitas, A. Donato, J.G. Monteiro, Controlled trial of liquid monopolar
electrocoagulation in bleeding peptic ulcers, Am. J. Gastroenterol. 80 (11)
(1985) 853e857.
[65] I.A. MacLeod, P.R. Mills, J.F. MacKenzie, et al., Neodymium yttrium aluminium
garnet laser photocoagulation for major haemorrhage from peptic ulcers and
single vessels: a single blind controlled study, Br. Med. J. Clin. Res. Ed. 286
(6362) (1983) 345e348.
[66] M.B. Leon, R. Kornowski, W.E. Downey, et al., A blinded, randomized, placebo-
controlled trial of percutaneous laser myocardial revascularization to improve
angina symptoms in patients with severe coronary disease, J. Am. Coll. Car-
diol. 46 (10) (2005) 1812e1819.
[67] D.A. Corley, P. Katz, J.M. Wo, et al., Improvement of gastroesophageal reﬂux
symptoms after radiofrequency energy: a randomized, sham-controlled trial,
Gastroenterology 125 (3) (2003) 668e676.
[68] J.S. Scolapio, C.J. Gostout, K.W. Schroeder, et al., Dysphagia without endo-
scopically evident disease: to dilate or not? Am. J. Gastroenterol. 96 (2) (2001)
327e330.
[69] A. Geliebter, P.M. Melton, D. Gage, et al., Gastric balloon to treat obesity: a
double-blind study in nondieting subjects, Am. J. Clin. Nutr. 51 (4) (1990)
584e588.
[70] K.D. Lindor, R.W. Hughes Jr., D.M. Ilstrup, et al., Intragastric balloons in
comparison with standard therapy for obesityea randomized, double-blind
trial, Mayo Clin. Proc. 62 (11) (1987) 992e996.
[71] E.M. Mathus-Vliegen, G.N. Tytgat, E.A. Veldhuyzen-Offermans, Intragastric
balloon in the treatment of super-morbid obesity. Double-blind, sham-
controlled, crossover evaluation of 500-milliliter balloon, Gastroenterology 99
(2) (1990) 362e369.
[72] H. Meshkinpour, D. Hsu, S. Farivar, Effect of gastric bubble as a weight
reduction device: a controlled, crossover study, Gastroenterology 95 (3)
(1988) 589e592.
[73] J.T. Maurer, J.U. Sommer, G. Hein, et al., Palatal implants in the treatment of
obstructive sleep apnea: a randomised, placebo-controlled single-centre trial,
Eur. Arch. Otorhinolaryngol. 269 (7) (2012) 1851e1856.
[74] A.J. London, J.B. Kadane, Placebos that harm: sham surgery controls in clinical
trials, Stat. Methods Med. Res. 11 (5) (2002) 413e427.
[75] T. Swift, R. Huxtable, The ethics of sham surgery in Parkinson's disease: back
to the future? Bioethics 27 (4) (2013) 175e185.
[76] S. Polgar, J. Ng, Ethics, methodology and the use of placebo controls in surgical
trials, Brain Res. Bull. 67 (4) (2005) 290e297.
[77] A. Hrobjartsson, P.C. Gotzsche, Is the placebo powerless? An analysis of clin-
ical trials comparing placebo with no treatment, N. Engl. J. Med. 344 (21)
(2001) 1594e1602.
[78] R.G. Grossman, Cell transplantation in Parkinson's disease: implications for
human clinical trials, Neurosurgery 49 (3) (2001) 580e582.
[79] L. Laine, Multipolar electrocoagulation in the treatment of active upper
gastrointestinal tract hemorrhage. A prospective controlled trial, N. Engl. J.
Med. 316 (26) (1987) 1613e1617.
